found that patients with high PD-L1 expression in tumor tissues had a better outcome of re-treatment with anti-PD-1 antibodies, with an ORR of 22.7%, compared to an ORR of 9.1% for those with low expression (26). The gene discussed is PDCD1; the disease is neoplasm.